COVID-19: impact of vaccination in myeloma patients.

Hoornaert, E; Dachy, F; Hansenne, A; Bailly, S; van Maanen, A; Gruson, D; Vekemans, M-C

Hoornaert, E; Dachy, F; Hansenne, A; Bailly, S; van Maanen, A; Gruson, D; Vekemans, M-C.

Afiliação

Hoornaert E; Department of Internal Medicine and Infectious Diseases, Cliniques universitaires Saint Luc, 10 avenue Hippocrate, 1200 Woluwe Saint Lambert, Brussels, Belgium. Ellen.hoornaert@uclouvain.be.
Dachy F; Department of Hematology, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium.
Hansenne A; Department of Hematology, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium.
Bailly S; Department of Hematology, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium.
van Maanen A; Statistical Support Unit, King Albert II Institute, Cliniques Universitaires Saint Luc, 1200, Brussels, Belgium.
Gruson D; Department of Laboratory Medicine, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium.
Vekemans MC; Department of Hematology, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium.

Ann Hematol ; 101(7): 1607-1608, 2022 07.

Article em En | MEDLINE | ID: mdl-35411439

Assuntos

COVID-19; Mieloma Múltiplo; COVID-19/prevenção & controle; Células Dendríticas; Humanos; Mieloma Múltiplo/terapia; Vacinação

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Mieloma Múltiplo Limite: Humans Idioma: En Revista: Ann Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google